Abivax (AAVXF) Free Cash Flow (2024 - 2026)

Abivax has reported Free Cash Flow for 3 years, with the latest figure at -$59.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 69.01% year-over-year to -$59.1 million in Q1 2026; TTM through Mar 2026 was -$187.4 billion, a 14.31% decrease from a year earlier, with the FY2025 full-year figure at -$187.4 billion, down 14.3% from the prior year.
• Free Cash Flow was -$59.1 million for Q1 2026 at Abivax, up from -$187.2 billion in the prior quarter.
• The five-year high for Free Cash Flow was -$35.0 million in Q1 2025, with the low at -$187.2 billion in Q4 2025.
• Average Free Cash Flow over 3 years is -$39.0 billion, with a median of -$54.1 million recorded in 2024.
• The largest YoY upside for Free Cash Flow was 30.22% in 2025 against a maximum downside of 116.38% in 2025.
• Over 3 years, Free Cash Flow stood at -$163.8 billion in 2024, then dropped by 14.29% to -$187.2 billion in 2025, then jumped by 99.97% to -$59.1 million in 2026.
• The last three Free Cash Flow figures came in at -$59.1 million (Q1 2026), -$187.2 billion (Q4 2025), and -$83.3 million (Q3 2025), per Business Quant data.